Michael Dougherty was appointed a member of Idera’s Board of Directors in April 2019 and was elected Chair of the Board in April 2021. Mr. Dougherty also serves on the boards of directors of Trevena, Inc. and Marinus Pharmaceuticals, Inc., both publicly traded life sciences companies.
Mr. Dougherty previously served as the executive chairman of Celator Pharmaceuticals, Inc. from August 2015 until its acquisition by Jazz Pharmaceuticals in July 2016, and as a director of Celator from July 2013 to July 2016. Mr. Dougherty also previously served in a variety of senior leadership positions in the biopharmaceutical industry, including Chief Executive Officer of Kalidex Pharmaceuticals, Chief Executive Officer of Adolor Corporation, Chief Operating Officer of Genomics Collaborative, Chief Executive Officer of Genaera Corporation, and Chief Financial Officer at Centocor, Inc. Mr. Dougherty also served on the boards of directors of Foundation Medicine, Aviragen Therapeutics, and Cempra, and of ViroPharma Incorporated from 2004 until its acquisition by Shire in 2014.
Mr. Dougherty holds a Bachelor of Science in Accounting from Villanova University.